Prostaglandin E2 is a potent inhibitor of epithelial-to-mesenchymal transition: interaction with hepatocyte growth factor.
about
Epithelial-to-Mesenchymal Transition in Diabetic Nephropathy: Fact or Fiction?Therapeutic strategies for synchronous and multiple liver metastases from colorectal cancerConcise review: clinical translation of wound healing therapies based on mesenchymal stem cellsSalvianolic acid B reverses the epithelial-to-mesenchymal transition of HK-2 cells that is induced by transforming growth factor-βStable Ectopic Expression of ST6GALNAC5 Induces Autocrine MET Activation and Anchorage-Independence in MDCK CellsDiminished prostaglandin E2 contributes to the apoptosis paradox in idiopathic pulmonary fibrosisProstaglandins in cancer cell adhesion, migration, and invasionMesenchymal stem cell therapy for attenuation of scar formation during wound healing.cAMP and Epac in the regulation of tissue fibrosis.Macrophages programmed by apoptotic cells inhibit epithelial-mesenchymal transition in lung alveolar epithelial cells via PGE2, PGD2, and HGFPPARγ activation following apoptotic cell instillation promotes resolution of lung inflammation and fibrosis via regulation of efferocytosis and proresolving cytokines.A comparison of epithelial-to-mesenchymal transition and re-epithelializationHepatocyte growth factor regulates cyclooxygenase-2 expression via beta-catenin, Akt, and p42/p44 MAPK in human bronchial epithelial cells.Cox-2 inactivates Smad signaling and enhances EMT stimulated by TGF-beta through a PGE2-dependent mechanisms.Eicosanoid lipid mediators in fibrotic lung diseases: ready for prime time?Glomerular parietal epithelial cells of adult murine kidney undergo EMT to generate cells with traits of renal progenitors.TGF-β1 as a therapeutic target for pulmonary fibrosis and COPD.Chronic kidney disease: targeting prostaglandin E2 receptors.Mesenchymal stem cell-based therapy for nonhealing wounds: today and tomorrow.The emerging role of hepatocyte growth factor in renal diseases.Cytosolic phospholipase A2α increases proliferation and de-differentiation of human renal tubular epithelial cells.Thrombin induces epithelial-mesenchymal transition via PAR-1, PKC, and ERK1/2 pathways in A549 cells.Relationship of Cell Proliferating Marker Expressions with PGE(2) Receptors in Regenerating Rat Renal Tubules after Cisplatin InjectionProstaglandin D2 inhibits TGF-beta1-induced epithelial-to-mesenchymal transition in MDCK cells.The antifibrotic effects of plasminogen activation occur via prostaglandin E2 synthesis in humans and mice.CD44v3-v10 reduces the profibrotic effects of TGF-β1 and attenuates tubular injury in the early stage of chronic obstructive nephropathy.Modulation of the TGF-β1-induced epithelial to mesenchymal transition (EMT) mediated by P1 and P2 purine receptors in MDCK cells.Coordinated induction of cyclooxygenase-2/prostaglandin E2 and hepatocyte growth factor by apoptotic cells prevents lung fibrosis.The A2B Adenosine Receptor Modulates the Epithelial- Mesenchymal Transition through the Balance of cAMP/PKA and MAPK/ERK Pathway Activation in Human Epithelial Lung Cells.Recent Updates on Treatment of Ocular Microbial Infections by Stem Cell Therapy: A Review.Chemopreventive effect of phosphodieasterase-4 inhibition in benzo(a)pyrene-induced murine lung cancer model.
P2860
Q26782283-3BA85CC6-BC34-410D-81CE-7A869B1F60A4Q26829522-F84CE2E0-9A3E-4E4B-8150-DFEFABA2AA81Q26830539-8E8D73AC-14C7-4DDB-858B-C736047ADAEAQ28236906-2F69CF0B-5263-4BCE-9CF6-0047B3155808Q28553147-BF3D6782-F10F-431B-AD15-FA7A9B2CFDABQ33988131-679DF130-B0E7-4586-ABDD-0A3F1F19C403Q35821653-6A8CCAC3-105D-4319-AFD1-AA8A2F76125FQ36084821-A5E016EE-9E1E-47F7-B117-208EF5F9107BQ36159130-CDAB93EF-17FC-46A1-8CA4-3D874E941A14Q36579632-521A1B4A-1AEE-4F91-881C-F16B54036399Q36605155-A5986068-986B-448B-B6BB-2DCE48A8B5CDQ36678367-97F2B509-EE39-41E4-8343-A086DE4C9287Q36719452-DC646853-BBF5-4C88-AC88-C68A37957D0DQ36959011-B84B9849-A4FE-4617-A27B-DC0637DCB152Q36970702-E7A0AA74-D9C3-433E-B4B6-29ECB8E01692Q37294529-9C53E5F3-A359-45A7-BCC5-0BB7C5BF2264Q38177343-F33EA933-800B-4EB3-8B40-C8564D81E16EQ38223323-5E46CF07-BD42-4959-8452-289C63B2F973Q38422834-45AB6E59-C077-4BED-A087-E89537D53E0EQ38605788-9F54265E-8C6B-41D1-91CA-2B000F0B1BE0Q38750539-66D24DA4-C47E-4D27-B2B8-744EB36DB6C9Q39114742-AA981C42-BBFA-42D2-AC96-10C949270A20Q39703981-DA8FB354-FE7C-4990-BCD1-C78E82805523Q40245828-EB27000F-199A-4DFE-99E7-F3C15CA7739FQ40794888-B6831E23-CC07-433E-8EEC-004E86D912EEQ45715929-E09F5D62-5E8B-49B4-9330-48759ACE504DQ47117582-0197DACB-2668-4801-BCDC-A39A3F0DFD69Q47841072-0881FE84-B792-4D7F-98AE-DFB802E63CBCQ50041957-7834CBE2-D744-47B3-9492-D4F0A0568945Q50042214-B1559584-3D5C-4D61-A3C1-D4654C973FBFQ51109588-34616FC0-F92B-43D3-8C5F-36E1A36A65A1
P2860
Prostaglandin E2 is a potent inhibitor of epithelial-to-mesenchymal transition: interaction with hepatocyte growth factor.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Prostaglandin E2 is a potent i ...... with hepatocyte growth factor.
@en
type
label
Prostaglandin E2 is a potent i ...... with hepatocyte growth factor.
@en
prefLabel
Prostaglandin E2 is a potent i ...... with hepatocyte growth factor.
@en
P2093
P2860
P1476
Prostaglandin E2 is a potent i ...... with hepatocyte growth factor.
@en
P2093
Aihua Zhang
Mong-Heng Wang
Tianxin Yang
Zheng Dong
P2860
P304
P356
10.1152/AJPRENAL.00480.2005
P577
2006-07-25T00:00:00Z